Community/Retail

Jillian Fetzner, MSN, APRN-CNP, described how integrating pharmacists into a collaborative practice agreement processed 3750 diabetes refill requests without provider involvement.

Dave Dixon, PharmD, breaks down the key cardiovascular and kidney risk management updates in the 2026 ADA Standards of Care and what they mean for pharmacy practice.

Both slow and fast transition periods were safe and effective, with minimal adverse events.

A pharmacist-led refill authorization program in endocrinology eliminated 3750 refill requests from provider in-baskets in 2025.

PET scans show long COVID mood and brain fog link to limbic activity, not widespread brain inflammation, reshaping COVID-19 treatment targets.

ADA data show CGM plus pharmacist groups helps seniors with type 2 diabetes prevent hypoglycemia, boost confidence, and prompt safer meds.

The policy direction is clear, but the regulatory mechanics are still working their way through the system.

Recent developments reflect a broader shift toward individualized, biologically informed care.

The FDA approved the oral antiviral ensitrelvir (Xocova; Shionogi & Co, Ltd) for post-exposure prophylaxis (PEP) of COVID‑19 in adults and adolescents 12 years and older.

Emerging evidence suggests that some individuals develop nutritional deficiencies during treatment, while others experience biologically driven GLP-1 resistance.

Disparities in education access and quality, income level, and race and ethnicity are SDoH that make a major impact on diabetes and its management in the US.

With no new kidney-protective therapies approved in T1D for over three decades, experts break down the clinical significance of finerenone's FDA priority review and what pharmacists need to know.

Afrezza is the only ultra rapid-acting inhaled insulin approved by the FDA to improve glycemic control in children, adolescent, and adult patients with diabetes.

A cross-sectional analysis of nearly 30,000 US adults found that economic instability, food insecurity, limited education, and poor social context each independently elevated the odds of advanced cardiovascular-kidney-metabolic (CKD) syndrome—but not equally across all groups.

The ability to anticipate access delays, navigate benefit changes, and protect continuity of care has become a defining role of modern pharmacy practice.

Dermatology care for skin of color can be improved by understanding inflammation-driven hyperpigmentation, safer treatments, and addressing education gaps that delay diagnosis and worsen outcomes.

New household data show recent COVID-19 shots cut at-home spread by 43%, strengthening pharmacist counseling on staying up to date.

Tim Casey addresses what this means for health care providers and pharmacists, and why this may represent a rare window for meaningful, bipartisan reform.

Joe DePinto of McKesson outlines the workflow barriers slowing CGT migration to community oncology, the reimbursement reforms needed to scale access, and the pharmacist’s pivotal role in making it all work.

Craig Beavers highlights 3 major developments in cardiovascular and cardiometabolic medicine that pharmacists should have on their radar.

Joe DePinto of McKesson discusses how payers, providers, and employers diverge on CGT reimbursement—and why outcomes-based payment models may hold the key to broader patient access.

As Novo Nordisk transitions patients from Rybelsus to newer, higher-efficacy oral semaglutide formulations, pharmacists are on the front lines of counseling, dosing clarification, and adverse effect management.

Bundibugyo Ebola spreads in DRC and Uganda as the WHO declares a public health emergency of international concern; learn the case counts, travel alerts, and pharmacist readiness steps.

Clinical pharmacists may play an increasingly important role in longitudinal metabolic care, medication optimization, patient education, and multidisciplinary peptide management.

Spencer Durham, PharmD, FCCP, BCPS, BCIDP, discusses why hepatitis B remains an active public health threat.

The approval ends a decades-long gap in care for patients with chronic hepatitis delta virus (HDV) infection, a serious and life-threatening coinfection with hepatitis B that can rapidly progress to cirrhosis, liver cancer, and liver failure.

A board-certified psychiatric pharmacist breaks down how systemic fragmentation, access barriers, and policy gaps are undermining schizophrenia treatment—and what must change.